Exact Sciences Corporation EXAS reported better-than-expected second-quarter financial results on Wednesday.Exact Sciences reported quarterly losses of 9 cents per share, which beat the analyst consensus estimate of losses of 32 cents by 71.88%.The company reported quarterly sales of $699.264 million which beat the analyst consensus estimate of $690.003 million. Screening revenue was $532 million, a 15% increase, and Precision Oncology revenue was $168 million, an increase of 6%.Also, the company announced ...